PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
1.79
Current Ratio 0.75–0.9x Drug Manufacturers - Specialty & Generic median of 2.17. John Neff would want to see better short-term coverage or stable cash flows.
1.32
Quick Ratio 0.75–0.9x Drug Manufacturers - Specialty & Generic median of 1.50. John Neff might push for better working capital control.
0.48
Cash Ratio 0.5–0.75x Drug Manufacturers - Specialty & Generic median of 0.67. Guy Spier might see partial vulnerability if obligations spike.
-17.90
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
0.20
Short-term coverage of 0.20 versus zero Drug Manufacturers - Specialty & Generic median. Walter Schloss would verify if our cash flow management provides advantages.